WP
NKTR icon

Woodline Partners’s Nektar Therapeutics NKTR Stock Holding History

Woodline Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.9M Buy
470,875
+55,540
+13% +$4.06M 0.1% 265
2026
Q1 		$29.9M Buy
415,335
+311,335
+299% +$17.7M 0.11% 248
2025
Q4 		$4.4M Sell
104,000
-129,059
-55% -$7.22M 0.02% 653
2025
Q3 		$13.3M Sell
233,059
-13,086
-5% -$433K 0.06% 373
2025
Q2 		$6.36M Buy
246,145
+20
+0% +$225 0.03% 518
2025
Q1 		$2.51M Sell
246,125
-85,509
-26% -$1.12M 0.02% 631
2024
Q4 		$4.63M Buy
331,634
+216,189
+187% +$3.81M 0.03% 501
2024
Q3 		$2.25M Buy
115,445
+73,918
+178% +$1.41M 0.02% 465
2024
Q2 		$772K Buy
+41,527
New +$875K 0.01% 478
2022
Q1 		– Sell
-65,774
Closed -$13.3M – 789
2021
Q4 		$13.3M Buy
+65,774
New +$14.3M 0.19% 148

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's NKTR Position: Q2 2026 in Review

Woodline Partners increased its Nektar Therapeutics (NKTR) stake by 13% in Q2 2026, buying an estimated $4.06M and bringing the position to 470,875 shares worth $32.9M. The position accounts for 0.1% of the portfolio, ranked #265.

Woodline Partners first reported a position in NKTR in Q4 2021 and has held it in 10 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Woodline Partners held 470,875 shares of Nektar Therapeutics worth $32.9M as of Q2 2026.
  • Woodline Partners bought 55,540 Nektar Therapeutics shares in Q2 2026, an estimated $4.06M.
  • Nektar Therapeutics made up 0.1% of Woodline Partners's portfolio in Q2 2026, its #265 holding.
  • Woodline Partners first reported a position in Nektar Therapeutics in Q4 2021 and has held it in 10 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.